CLINICAL TRIALS PROFILE FOR FAMOTIDINE AND IBUPROFEN

All Clinical Trials for Famotidine And Ibuprofen

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00450216 ↗	Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment	Completed	Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 3	2007-03-01	The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.
NCT00450658 ↗	Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers	Completed	Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 3	2007-03-01	The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.
NCT00613106 ↗	Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)	Completed	Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 3	2007-09-01	The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.
NCT00984815 ↗	Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment	Completed	Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 3	2009-09-01	The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
NCT01563185 ↗	Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis	Completed	Pediatric Rheumatology Collaborative Study Group	Phase 4	2012-04-01	The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.
NCT01563185 ↗	Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis	Completed	Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 4	2012-04-01	The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.
NCT03695172 ↗	Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section	Terminated	Duke University	Phase 4	2019-09-12	The purpose of this prospective single center, randomized study is to determine if ultrasound guided Transversus Abdominis Plane (TAP), Quadratus Lumborum (QL), and Erector Spinae Plane (ESP) blocks decrease opioid consumption in subjects undergoing elective cesarean section.

Clinical Trial Conditions for Famotidine And Ibuprofen

Condition Name

Condition Name for Famotidine And Ibuprofen
Intervention	Trials
Pain, Postoperative	3
Osteoarthritis	2
Analgesia	2
Rheumatoid Arthritis	2

Condition MeSH

Condition MeSH for Famotidine And Ibuprofen
Intervention	Trials
Pain, Postoperative	3
Low Back Pain	2
Agnosia	2
Back Pain	2

Clinical Trial Locations for Famotidine And Ibuprofen

Trials by Country

Trials by Country for Famotidine And Ibuprofen
Location	Trials
United States	11

Trials by US State

Trials by US State for Famotidine And Ibuprofen
Location	Trials
Texas	4
Pennsylvania	2
North Carolina	1
Massachusetts	1
Louisiana	1

Clinical Trial Progress for Famotidine And Ibuprofen

Clinical Trial Phase

Clinical Trial Phase for Famotidine And Ibuprofen
Clinical Trial Phase	Trials
PHASE2	2
Phase 4	2
Phase 3	4

Clinical Trial Status

Clinical Trial Status for Famotidine And Ibuprofen
Clinical Trial Phase	Trials
Completed	5
NOT_YET_RECRUITING	2
Terminated	1

Clinical Trial Sponsors for Famotidine And Ibuprofen

Sponsor Name

Sponsor Name for Famotidine And Ibuprofen
Sponsor	Trials
Horizon Pharma Ireland, Ltd., Dublin Ireland	5
Texas Scottish Rite Hospital for Children	2
Pediatric Rheumatology Collaborative Study Group	1

Sponsor Type

Sponsor Type for Famotidine And Ibuprofen
Sponsor	Trials
Industry	5
Other	4

Clinical Trials Update, Market Analysis, and Projection for Famotidine and Ibuprofen

Last updated: January 31, 2026

Summary

This report provides a comprehensive overview of the current clinical trial landscape, market dynamics, and future projections for Famotidine and Ibuprofen. Both drugs are well-established, with Famotidine primarily used for gastric acid reduction, and Ibuprofen as a widely used nonsteroidal anti-inflammatory drug (NSAID). Recent clinical trial activities, evolving regulatory landscapes, and market trends are examined, emphasizing their implications for stakeholders. Data-driven forecasts and competitive positioning insights are included to inform strategic decisions.

---

Clinical Trials Landscape for Famotidine and Ibuprofen

What is the status of clinical trials involving Famotidine?

Famotidine has experienced renewed clinical interest amidst emerging evidence suggesting potential applications beyond its traditional use for gastroesophageal reflux disease (GERD). Notably, investigations include:

Trial Phase	Number of Trials	Focus Areas	Key Findings / Status	Sources
Phase I & II	15	COVID-19, gastritis, Barrett's oesophagus	Mixed outcomes; some studies indicating potential benefit	[1], [2]
Phase III	2	Helicobacter pylori eradication, GERD maintenance	Ongoing; no conclusive results yet	[3]

COVID-19 Repurposing Studies:
Famotidine garnered attention after observational reports suggested decreased severity of COVID-19 in patients taking it (e.g., Freedberg et al., 2020). Several randomized controlled trials (RCTs) are in progress [1], aiming to validate these findings.

What is the clinical trial activity for Ibuprofen?

Ibuprofen's profile remains predominantly centered on its anti-inflammatory and analgesic properties, with ongoing trials exploring:

Trial Phase	Number of Trials	Focus Areas	Emerging Applications	Sources
Phase III	25	Osteoarthritis, rheumatoid arthritis, pain management	Emerging data on COVID-19 related inflammation, pediatric COVID-19 management	[4], [5]
Phase IV	30	Pharmacovigilance, long-term safety in chronic conditions	Real-world safety, drug interaction studies	[6]

Public Health and COVID-19:
Given its widespread use, numerous observational studies assess Ibuprofen’s safety profile during COVID-19, with some conflicting evidence on risk of worsening outcomes [7].

---

Market Analysis for Famotidine and Ibuprofen

Market Size & Revenue (2022)

Drug	Global Market Size (USD Million)	Key Regions	Growth Rate (CAGR 2022-2027)	Major Players	References
Famotidine	$1,150	US, Europe, Asia-Pacific	4.2%	Merck, Mylan, Cipla	[8]
Ibuprofen	$3,450	North America, EU, APAC	3.8%	Johnson & Johnson, Sandoz, Amneal	[9]

Market Drivers & Challenges

Famotidine:

• Drivers: Interest in COVID-19 applications; aging populations with GERD; increasing demand for affordable gastrointestinal remedies.
• Challenges: Generic market saturation; limited pipeline of novel formulations; regulatory uncertainties around off-label use.

Ibuprofen:

• Drivers: Continuous use as over-the-counter (OTC) analgesic; expansion into pediatric and chronic pain markets; increasing awareness of anti-inflammatory benefits.
• Challenges: Stringent safety regulations following adverse event reports; availability of alternatives like acetaminophen and NSAID combinations.

Regulatory and Policy Influences

• FDA: Recently updated warnings regarding NSAID use during COVID-19 and specific contraindications.
• EMA: Extended approval for pediatric use of Ibuprofen; renewed interest in Famotidine's off-label uses under emergency protocols [10].

---

Future Market Projection (2023–2028)

Parameter	Famotidine	Ibuprofen
Projected Market Size (2028, USD Million)	$1,350	$4,200
Compound Annual Growth Rate (CAGR)	4.5%	4.2%
Key Growth Drivers	COVID-19 research; aging population	OTC and chronic pain market expansion
Potential Risks	Regulatory restrictions; generic price erosion	Safety concerns; competition from novel NSAIDs

---

Comparative Analysis

Aspect	Famotidine	Ibuprofen
Original Indication	GERD, ulcers	Pain, fever, inflammation
Recent Emerging Use	COVID-19 (possible antiviral/anti-inflammatory)	COVID-19 related inflammation; pediatric applications
Market Maturity	Mature but with interest in off-label trials	Mature, OTC mainstay
Regulatory Environment	Slightly evolving, with increased scrutiny due to off-label claims	Stable but with vigilance over safety signals
Patent / Patent Expiry	No recent patents; mostly generic	Wide generic availability, patent expirations ongoing

---

Deep Dive: Strategic Considerations

For Pharmaceutical Companies

• Famotidine:

  • Opportunities: Invest in confirmatory RCTs for COVID-19; develop formulations suitable for targeted demographics (e.g., pediatric).
  • Risks: Off-label use may face regulatory hurdles; patent expiries diminish exclusivity.

• Ibuprofen:

  • Opportunities: Innovate safer, long-acting formulations; explore combination therapies; expand indications for pediatric and chronic conditions.
  • Risks: Anti-inflammatory safety concerns; market saturation.

For Investors & Market Analysts

• Focus on pipeline developments and regulatory news impacting the commercial viability.
• Monitor emerging trial results, particularly for Famotidine in COVID-19 applications.
• Evaluate macroeconomic factors influencing OTC vs. prescription drug markets.

---

FAQs

1. What are the latest clinical trial outcomes for Famotidine in COVID-19?

Current trials have yet to produce conclusive evidence. Some retrospective analyses suggest reduced severity, but randomized controlled trials (RCTs) are ongoing to validate these findings [1].

2. How does the safety profile of Ibuprofen impact its market growth?

While generally safe at recommended doses, adverse events such as gastrointestinal bleeding and cardiovascular risks have prompted regulatory alerts [7]. This influences prescriber and consumer confidence but has limited impact on OTC sales due to longstanding safety data.

3. What regulatory hurdles could affect future Famotidine approvals?

Off-label use restrictions, safety concerns from rare adverse effects, and evolving guidelines related to COVID-19 applications may lead to increased regulatory scrutiny and possible restrictions [10].

4. How are patent expiries influencing market competition for these drugs?

Most patent protections for Famotidine have expired, leading to significant generic competition. Ibuprofen's patents for specific formulations continue to expire, fostering price competition and market entry of generics.

5. What are the key indicators to watch for assessing future market potential?

• Results from ongoing clinical trials, especially for Famotidine in COVID-19 indications.
• Regulatory decisions and policy shifts concerning off-label indications.
• Expansion of OTC formulations and new combination products.
• Market penetration of biosimilars or novel formulations enhancing safety and efficacy.

---

Key Takeaways

• Clinical Research Focus:

  • Famotidine's potential repurposing for COVID-19 is under active investigation; further robust RCTs are critical for clinical adoption.
  • Ibuprofen continues broad application, with ongoing trials expanding into pediatric and COVID-19 inflammatory uses.

• Market Outlook:

  • Famotidine's market remains modest but poised for growth if COVID-19 efficacy is validated; projected CAGR of ~4.5%.
  • Ibuprofen maintains a dominant OTC market with a forecasted CAGR of over 4%, driven by existing demand and new formulation opportunities.

• Strategic Implications:

  • Developers should consider pipeline innovation, regulatory navigation, and safety profile management.
  • Investors should monitor trial outcomes and policy developments as primary market catalysts.

• Regulatory & Safety Factors:

  • Vigilance regarding safety signals and guidelines is necessary to mitigate market risks and preserve confidence.

---

References

[1] Freedberg, D. E., et al. (2020). Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients. medRxiv.
[2] ClinicalTrials.gov. (2022). Famotidine COVID-19 Trials.
[3] European Medicines Agency. (2022). Summary of Product Characteristics for Famotidine.
[4] WHO International Clinical Trials Registry Platform. (2022). Ibuprofen COVID-19 trials.
[5] PubMed Central. (2022). Pediatric CBD and NSAID studies.
[6] U.S. FDA. (2022). Post-marketing surveillance reports for NSAIDs.
[7] WHO. (2022). NSAID safety guidelines.
[8] MarketWatch. (2022). Famotidine Market Analysis; [9] Grand View Research. (2022). Ibuprofen Market Overview.
[10] EMA. (2022). Regulatory updates on NSAID use during COVID-19.

---

This detailed market and clinical landscape analysis is intended to support strategic decision-making for pharmaceutical companies, investors, and industry stakeholders.